250 related articles for article (PubMed ID: 15190515)
1. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Spivak JL
Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
3. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.
Kralovics R; Buser AS; Teo SS; Coers J; Tichelli A; van der Maas AP; Skoda RC
Blood; 2003 Sep; 102(5):1869-71. PubMed ID: 12730106
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
Kralovics R; Skoda RC
Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Spivak JL
Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of clonal development in chronic myeloproliferative disorders.
Ferraris AM; Mangerini R; Racchi O; Rapezzi D; Rolfo M; Casciaro S; Gaetani GF
Am J Hematol; 1999 Feb; 60(2):158-60. PubMed ID: 9929111
[TBL] [Abstract][Full Text] [Related]
7. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.
Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A
Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836
[TBL] [Abstract][Full Text] [Related]
8. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
[TBL] [Abstract][Full Text] [Related]
9. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
10. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
[TBL] [Abstract][Full Text] [Related]
11. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
Moliterno AR; Hankins WD; Spivak JL
N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
[TBL] [Abstract][Full Text] [Related]
12. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.
Goerttler PS; Steimle C; März E; Johansson PL; Andreasson B; Griesshammer M; Gisslinger H; Heimpel H; Pahl HL
Blood; 2005 Oct; 106(8):2862-4. PubMed ID: 15985544
[TBL] [Abstract][Full Text] [Related]
13. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles FJ; Pierce S; Albitar M
Cancer; 2000 Feb; 88(3):570-6. PubMed ID: 10649249
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
15. Towards a molecular understanding of polycythemia rubra vera.
Pahl HL
Eur J Biochem; 2000 Jun; 267(12):3395-401. PubMed ID: 10848954
[TBL] [Abstract][Full Text] [Related]
16. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.
Mitterbauer G; Winkler K; Gisslinger H; Geissler K; Lechner K; Mannhalter C
Am J Clin Pathol; 1999 Jul; 112(1):93-100. PubMed ID: 10396290
[TBL] [Abstract][Full Text] [Related]
17. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
18. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
19. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.
Moliterno AR; Williams DM; Rogers O; Spivak JL
Blood; 2006 Dec; 108(12):3913-5. PubMed ID: 16912229
[TBL] [Abstract][Full Text] [Related]
20. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
Liu E; Jelinek J; Pastore YD; Guan Y; Prchal JF; Prchal JT
Blood; 2003 Apr; 101(8):3294-301. PubMed ID: 12515724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
